Number of patients by type of treatment, breakdown of patients by age, and monthly drug costs
| Treatment . | Age, <75 yr . | Age, ≥75 yr . | Total . | Cost per month, JPY . |
|---|---|---|---|---|
| TKI alone | 20 (6.9%) | 15 (13.5%) | 35 (8.8%) | 623 243 |
| IO–IO (nivolumab + ipilimumab) | 57 (19.8%) | 20 (18%) | 77 (19.3%) | 1 012 535 |
| IO–TKI (pembrolizumab + axitinib) | 34 (11.8%) | 9 (8.1%) | 43 (10.8%) | 971 919 |
| IO–TKI (avelumab + axitinib) | 20 (6.9%) | 17 (15.3%) | 37 (9.3%) | 1 616 042 |
| IO–TKI (nivolumab + cabozantinib) | 50 (17.4%) | 20 (18%) | 70 (17.5%) | 1 181 236 |
| IO–TKI (pembrolizumab + lenvatinib) | 107 (37.2%) | 30 (27%) | 137 (34.3%) | 1 104 981 |
| Treatment . | Age, <75 yr . | Age, ≥75 yr . | Total . | Cost per month, JPY . |
|---|---|---|---|---|
| TKI alone | 20 (6.9%) | 15 (13.5%) | 35 (8.8%) | 623 243 |
| IO–IO (nivolumab + ipilimumab) | 57 (19.8%) | 20 (18%) | 77 (19.3%) | 1 012 535 |
| IO–TKI (pembrolizumab + axitinib) | 34 (11.8%) | 9 (8.1%) | 43 (10.8%) | 971 919 |
| IO–TKI (avelumab + axitinib) | 20 (6.9%) | 17 (15.3%) | 37 (9.3%) | 1 616 042 |
| IO–TKI (nivolumab + cabozantinib) | 50 (17.4%) | 20 (18%) | 70 (17.5%) | 1 181 236 |
| IO–TKI (pembrolizumab + lenvatinib) | 107 (37.2%) | 30 (27%) | 137 (34.3%) | 1 104 981 |
TKI, tyrosine kinase inhibitor; IO, immune-oncology drug; JPY, Japanese yen
Number of patients by type of treatment, breakdown of patients by age, and monthly drug costs
| Treatment . | Age, <75 yr . | Age, ≥75 yr . | Total . | Cost per month, JPY . |
|---|---|---|---|---|
| TKI alone | 20 (6.9%) | 15 (13.5%) | 35 (8.8%) | 623 243 |
| IO–IO (nivolumab + ipilimumab) | 57 (19.8%) | 20 (18%) | 77 (19.3%) | 1 012 535 |
| IO–TKI (pembrolizumab + axitinib) | 34 (11.8%) | 9 (8.1%) | 43 (10.8%) | 971 919 |
| IO–TKI (avelumab + axitinib) | 20 (6.9%) | 17 (15.3%) | 37 (9.3%) | 1 616 042 |
| IO–TKI (nivolumab + cabozantinib) | 50 (17.4%) | 20 (18%) | 70 (17.5%) | 1 181 236 |
| IO–TKI (pembrolizumab + lenvatinib) | 107 (37.2%) | 30 (27%) | 137 (34.3%) | 1 104 981 |
| Treatment . | Age, <75 yr . | Age, ≥75 yr . | Total . | Cost per month, JPY . |
|---|---|---|---|---|
| TKI alone | 20 (6.9%) | 15 (13.5%) | 35 (8.8%) | 623 243 |
| IO–IO (nivolumab + ipilimumab) | 57 (19.8%) | 20 (18%) | 77 (19.3%) | 1 012 535 |
| IO–TKI (pembrolizumab + axitinib) | 34 (11.8%) | 9 (8.1%) | 43 (10.8%) | 971 919 |
| IO–TKI (avelumab + axitinib) | 20 (6.9%) | 17 (15.3%) | 37 (9.3%) | 1 616 042 |
| IO–TKI (nivolumab + cabozantinib) | 50 (17.4%) | 20 (18%) | 70 (17.5%) | 1 181 236 |
| IO–TKI (pembrolizumab + lenvatinib) | 107 (37.2%) | 30 (27%) | 137 (34.3%) | 1 104 981 |
TKI, tyrosine kinase inhibitor; IO, immune-oncology drug; JPY, Japanese yen
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
